Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE

News Daily News

ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE

December 22, 2020

Trickier Patients, Fewer Adverse Events in High-risk PCI: Impella PROTECT III Registry

News Conference News TCT 2020

Trickier Patients, Fewer Adverse Events in High-risk PCI: Impella PROTECT III Registry

October 18, 2020

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

Biggest Barriers to Cardiac CT? Old Myths, Fair Payment, and De-adoption

News Conference News SCCT 2020

Biggest Barriers to Cardiac CT? Old Myths, Fair Payment, and De-adoption

Yael L. Maxwell

July 22, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Conference News ACC 2020

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Michael O'Riordan

March 28, 2020

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

News Daily News

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

March 16, 2020

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

February 28, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.